Matthew Marton serves as the Genomics Lead in Merck & Co.’s Clinical Biomarker Development Laboratory, where his laboratory develops, validates, and implements pharmacodynamic and patient stratification assays into Merck clinical studies. His current work focuses on the application of genomic assays as molecular diagnostics. During his time at Merck (since 2001), his areas of interest have included functional genomics, technology, and method development, biomarker qualification, pharmacogenomics, and six sigma-based quality control methodology. He is a contributor to several Clinical Laboratory Standards Institute (CLSI) documents, including Molecular Diagnostic Testing for Genetic Diseases (MM01) and Microarrays for Cytogenetics and Oncology (MM21). Earlier in his career, he worked with Dr. S. Friend and Dr. L. Hartwell at the Seattle Project, a think tank for technology development, which led to the founding in 1997 of Rosetta Inpharmatics, a biotechnology company that was acquired by Merck in 2001. At Rosetta and subsequently at Merck, he led scientific efforts to create a GLP-like high throughput functional genomics laboratory. His training included a National Research Council postdoctoral fellowship at the National Institutes of Health (1991-1996), where he combined biochemistry and genomics to probe the mechanism of translational regulatory systems in S. cerevisiae. His graduate work at Princeton University (1985-1991) involved transcriptional activation mechanisms of DNA tumor viruses. He attended college in his home town of Cleveland, OH at Case Western Reserve University, from which he received the B.S. degree in biochemistry with honors in 1985.
Biography Updated on 11 August 2011